NEW YORK (GenomeWeb) – Epigenomics today said that its second quarter revenues rose 18 percent year over year.
The company's revenues for the three months ended June 30 reached €405,000 ($541,000), compared to €343,000 in Q2 2013.
Already have a GenomeWeb or 360Dx account?Login Now.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.
Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.
This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.